On June 22nd, 2026, ChartSpan Medical Technologies finalised its strategic acquisition of Validic, a prominent personal health data and healthcare Internet of Things (IoT) platform. Operating as a consolidated entity under the ChartSpan banner, the transaction establishes a unified clinical delivery layer that merges full-service virtual care teams with a scaled device-logistics and data normalisation ecosystem. The transaction bridges a historically fragmented healthcare dat

The global medical technology and healthcare technology sectors are undergoing a profound structural realignment, shifting from post-pandemic volume driven consolidation toward highly disciplined portfolio design. Corporate divestitures, spin-offs and carve-outs have become primary mechanisms for multinational healthtech organisations seeking to optimise operating margins, reduce debt and redeploy capital toward high-growth, high-margin clinical categories. Driven by macroeco

Clinical enterprises are undergoing a fundamental transformation in how they deploy, orchestrate and manage artificial intelligence workloads. The rapid integration of high-performance models into core workflows, ranging from real-time diagnostic imaging to predictive patient risk modelling and automated clinical documentation, has exposed the limits of traditional public cloud architectures. In response, healthcare systems are increasingly adopting sovereign artificial intel

The valuation of healthtech and medtech entities represents one of the most complex exercises in corporate finance, requiring analysts to bridge the gap between long-term scientific development, binary regulatory approvals, capital intensive commercialisation and rapid technological obsolescence. Within a discounted cash flow (DCF) model, the terminal value is the single most critical and sensitive component of a company's total implied valuation, typically constituting betwe

The global computing landscape is undergoing a structural realignment. Driven by the rapid scaling of generative artificial intelligence and deep learning, the historical trajectory toward centralised public cloud environments is being challenged by a highly optimised, decentralised paradigm. NVIDIA is at the forefront of this transition, promoting on-premises "AI Factories" and localised hardware architectures as the defining infrastructure for the next decade of technology

Here's what's moved in European HealthTech over the past week, with the sector's attention firmly on Amsterdam. On funding, the standout was Semble's £30M Series C, led by Revaia with Partech and Octopus Ventures, to expand its open, interoperable clinical platform into France and larger European groups. Around it, a cluster of smaller AI-led rounds: 01Health ($15M Series A, specialist healthcare infrastructure, UK),

Deep-tech health monitoring has emerged as a major point of convergence for consumer electronics and longevity science. A notable project in this landscape is Temple, a neuro-technology and biological monitoring startup founded in 2024 by Deepinder Goyal, the founder and executive chairman of the Indian consumer-internet giant Zomato.

Five thousand leaders, one in three of them holding an executive title, descended on the RAI Amsterdam from 15th to 18th June 2026 for HLTH Europe. The call to action this year was "Step Outside", a deliberate nudge to leave the comfort zone, look at familiar problems from unfamiliar angles, and find energy in collaboration across boundaries. For those of us who spend our days on the deal side of digital health, the phrase turned out to be an unusually accurate description of

The entry of Midjourney Inc. into the medical hardware sector represents a significant shift for a company previously known for subscription-based generative artificial intelligence software. Unveiled by Chief Executive Officer David Holz on June 17th 2026, under the newly formed "Midjourney Medical" division, the "Midjourney Scanner" is proposed as a full-body, high-throughput ultrasonic imaging system designed to capture a comprehensive three-dimensional map of internal hum

Tokenmaxxing emerged in early 2026 as a highly polarising workplace phenomenon within Silicon Valley engineering organisations. Defined as the deliberate maximisation of artificial intelligence token consumption, the practice was initially conceptualised by some management teams as a proxy metric for employee productivity and AI integration. The fundamental premise of tokenmaxxing is that higher token consumption correlates directly with greater utilisation of powerful AI cap

The global digital health sector is undergoing a structural realignment driven by the rapid integration of artificial intelligence, machine learning and large language models (LLMs). For over two decades, the valuation and operational viability of health information technologies were dictated by classic software-as-a-service (SaaS) unit economics. These legacy frameworks relied on highly predictable variables, primarily measured through customer lifetime value (LTV), customer

Nelson Advisors partner Lloyd Price has been interviewed by Healthcare Business International for their 'Sigma Healthcare drops out of talks to acquire Boots' story focused on the strategic M&A and IPO options available to Boots and their PE owners Sycamore Partners.

The European digital health and healthcare technology (HealthTech) landscape is undergoing a profound structural transformation, transitioning from an era of speculative, growth-at-all-costs capital deployment to a disciplined, metric-driven environment focused on unit economics, clinical utility, and artificial intelligence integration. While global bulge-bracket institutions continue to dominate mega-cap transactions, a highly specialised tier of boutique investment banks h

NHS ConfedExpo 2026 marked a decisive shift from abstract digital strategies to the pragmatic delivery of the NHS 10-Year Health Plan. The overwhelming consensus across Manchester’s exhibition halls last week was that the NHS can no longer simply "manage" its way through modern backlogs; it has to transform its way out.

The European healthcare technology and medical technology sectors have reached a definitive operational and financial inflection point. Following a period of post-pandemic recalibration, the transaction landscape has transitioned into an era of disciplined industrial maturity, widely characterised by market analysts as the "Great Rationalisation". The speculative business models of the early 2020s, which prioritised user acquisition and un-monetised top-line expansion, have b